INIS
patients
100%
blood cells
48%
plasma
45%
thrombosis
45%
thrombin
44%
phospholipids
32%
risks
29%
production
27%
in vitro
25%
biological markers
24%
storage
21%
applications
21%
lymphomas
21%
myeloid leukemia
21%
kinases
21%
tyrosine
21%
complement
16%
humans
12%
levels
10%
concentration
9%
apoptosis
9%
boron 19
9%
variations
8%
blood
8%
monoclonal antibodies
8%
hemolysis
8%
death
8%
diseases
8%
sensitivity
8%
investigations
6%
transfusions
6%
toxicity
6%
necrosis
6%
hematology
6%
endothelium
6%
tumors
5%
reduction
5%
comparative evaluations
5%
values
5%
reviews
5%
dimers
5%
proteins
5%
origin
5%
lactate dehydrogenase
5%
evaluation
5%
Medicine and Dentistry
Erythrocyte Concentrate
21%
microRNA
21%
Multidrug Resistance
21%
Acute Myeloid Leukemia
21%
Leukemia Cell
21%
HL60
21%
Procoagulant
21%
In Vitro
21%
Endothelial Cell
21%
Artery Thrombosis
21%
Tyrosine-Kinase Inhibitor
21%
Chronic Myelogenous Leukemia
21%
Drug Resistance
17%
Ponatinib
12%
Erythrocyte
10%
Thrombin
10%
Multidrug Resistance Protein 1
10%
Nilotinib
8%
Dasatinib
8%
Cancer Cell
7%
Phospholipid
7%
Keyphrases
Longitudinal Clinical Study
21%
Prospective Longitudinal Study
21%
Acute Myeloid Leukemia Cells
21%
Red Cell Concentrates
21%
Platelet-free Plasma
12%
Vesicle Production
9%
Circulating Extracellular Vesicles
6%
Procoagulant Phospholipids
6%